A generic89zr labeling method to quantify the in vivo pharmacokinetics of liposomal nanoparticles with positron emission tomography

Abstract

Liposomal nanoparticles are versatile drug delivery vehicles that show great promise in cancer therapy. In an effort to quantitatively measure their in vivo pharmacokinetics, we developed a highly efficient89Zr liposome-labeling method based on a rapid ligand exchange reaction between the membrane-permeable89Zr(8-hydroxyquinolinate)4 complex and the hydrophilic liposomal cavity-encapsulated deferoxamine (DFO). This novel89Zr-labeling strategy allowed us to prepare radiolabeled forms of a folic acid (FA)-decorated active targeting89Zr-FA-DFO-liposome, a thermosensitive89Zr-DFO-liposome, and a renal avid89Zr-PEG-DFO-liposome at room temperature with near-quantitative isolated radiochemical yields of 98%±1% (n=6), 98%±2% (n=5), and 97%±1% (n=3), respectively. These89Zr-labeled liposomal nanoparticles showed remarkable stability in phosphate-buffered saline and serum at 37°C without leakage of radioactivity for 48 h. The uptake of89Zr-FA-DFO-liposome by the folate receptor-overexpressing KB cells was almost 15-fold higher than the89Zr-DFO-liposome in vitro. Positron emission tomography imaging and ex vivo biodistribution studies enabled us to observe the heterogeneous distribution of the89Zr-FA-DFO-liposome and89Zr-DFO-liposome in the KB tumor xenografts, the extensive kidney accumulation of the89Zr-FA-DFO-liposome and89Zr-PEG-DFO-liposome, and the different metabolic fate of the free and liposome-encapsulated89Zr-DFO. It also unveiled the poor resistance of all three liposomes against endothelial uptake resulting in their catabolism and high uptake of free89Zr in the skeleton. Thus, this technically simple89Zr-labeling method would find widespread use to guide the development and clinical applications of novel liposomal nanomedicines.